We have previously shown that ex vivo insertion of a gene detected only in immunocompetent animals, confirming the encoding the mycobacterial heat shock protein-65 into role of T cells in tumour rejection. Treatment of tumour tumour cells results in their inability to form tumours in bearing mice with the heat shock gene-liposome complex mice. We report regression of highly malignant reticulum resulted in the production of antibodies against the tumour cell sarcomas (J774) after liposome-mediated gene transcells, indicating an increase in the antigenicity of the fer in vivo. Heat shock gene transfer resulted in tumour tumour after gene transfer. These results suggest that the regression both in immunocompetent and immunodeficient heat shock protein-65 gene could provide a novel SCID mice. Complete tumour eradication, however, was approach for the treatment of established tumours.
Introduction
weekly for 2 weeks. Tumour progression was compared Heat shock proteins (hsp) are induced by various forms to untreated and vector DNA-liposome-treated controls. of cellular stress to protect cells from environmental damUntreated and vector DNA-liposome-treated mice age. 1, 2 Many members of the hsp family are also essential developed highly malignant lymphoreticular neoplasms for cellular functions under physiologic conditions. 3, 4 composed of histiocytic cells growing in the peritoneal Involvement in protein folding and transport led to descavity and in most abdominal organs. Control mice ignation of hsps as molecular chaperones. 5 Hsps can receiving vector DNA-liposome injections showed a chaperone small antigenic peptides to MHC molecules small but significant decrease in tumour size (P Ͻ 0.05). for efficient antigen presentation. 6 It has been reported Hsp65-liposome gene therapy resulted in a large and that mice immunised with tumour-derived hsp fractions highly significant (P Ͻ 0.0001) reduction in tumour size associated with tumour-specific small peptides, develop in immunocompetent animals by day 18 compared with antitumour protection specific for the parent tumour both the 20 untreated and the 10 vector-treated controls cells. 7 ( Figure 1a ). After hsp gene therapy palpable tumours In addition to functioning as molecular chaperones, were found in three out of 20 immunocompetent Balb/c bacterial hsps are among the most potent antigenic stimmice. SCID mice receiving hsp65 gene therapy also uli for the mammalian immune system. We have predeveloped smaller tumours (P Ͻ 0.01) than the untreated viously shown, that tumour cells expressing a mycobacand vector-liposome-treated controls (Figure 1b ), but in terial hsp gene after in vitro gene transfer lose their ability 80% of the hsp-treated mice palpable tumours were to form tumours and induce a preventive antitumour detectable at autopsy. immune response. 8, 9 In this study we show the effectiveFlow cytometric DNA analysis of peritoneal samples ness of hsp65 gene transfer in vivo in the treatment of obtained from tumour bearing Balb/c mice confirmed the existing tumours.
presence of highly proliferative tumour cells (Figure 2a ). Hsp65-liposome treatment initiated on day 4 (as described for Figure 1 ) resulted in a significant decrease
Results
in the number of cells in G2/S phase (17.3 ± 5.4%) ( Figure  2b ) compared with 10 vector-liposome-treated controls Increased antitumour protection after hsp gene transfer (74.0 ± 6.3%) (P Ͻ 0.001). DNA histograms obtained from in vivo peritoneal samples of hsp65 gene-treated SCID mice Immunocompetent Balb/c and T cell-deficient SCID mice showed a decrease in S/G2 phase cells to 64.4 ± 12.3% were injected with 2 × 10 6 J774 cells into the peritoneal (Figure 2d ), compared with 85.6 ± 2.3% in vector-lipocavity. Four days later they received an intraperitoneal some-treated controls (Figure 2c ). This difference was not (i.p.) injection of 100 g hsp65 DNA complexed with statistically significant (P Ͻ 0. tained an hsp65-specific mRNA band not seen in they received the first injection of hsp65-liposome, repeated at 2 day intervals on four occasions. On day 21 autopsy was performed to determine if tumours were present and measure tumour size. In seven out of 10 hspliposome-treated mice no palpable tumour was found at autopsy and there was a significant decrease in tumour size compared with the 10 untreated controls (P Ͻ 0.001) ( Figure 4 ). J774 reticulum sarcoma is a tumour with aggressive in vivo growth characteristics (2 × 10 6 tumour cells injected i.p. cause death by day 22-26). Rapid regression of advanced tumours ( Figure 4 ) suggests that hsp65 gene transfer can be an effective treatment in late cancer. It proved to be essential to complex the hsp65 DNA to liposomes, since treatment of tumour bearing mice with peritoneal injections of naked DNA or preimmunisation of mice with intramuscular injections of naked DNA have not resulted in significant antitumour protection (data not shown).
Production of tumour-specific antibodies after in vivo hsp gene therapy Balb/c mice injected with J774 tumour cells alone produced no antibodies against the tumour ( Figure 5 ). Treatment of mice with vector-liposome complexes had no effect on antibody production. Intraperitoneal injections of the hsp65 gene complexed with liposomes into tumour bearing mice (as described for Figure 1 ) resulted in production of tumour-specific antibodies. Various dilutions of sera from hsp gene-treated animals tested by ELISA assay using the lysate of nonmodified J774 cells contained J774-specific antibodies but did not react with lysates from other tumours (Wehi-164 and Pu-518) (data not shown). These results confirm increased recognition of tumour-specific structures after hsp gene transfer.
Discussion
Our results demonstrate regression of established reticulum cell sarcomas after in vivo gene therapy with the mycobacterial hsp65 gene. Complete tumour rejection was achieved only in Balb/c mice with intact T cellmediated immunity. On the other hand, reduction in tumour size observed in hsp gene-treated SCID mice suggests that T cell-independent mechanisms such as NK cells or macrophages or changes in the cell cycle regu- cines containing mycobacterial hsps complexed with weakly antigenic peptide epitopes from pathogens have been shown to induce strong immune responses specific untreated and vector-liposome-treated animals ( Figure  3) . The positive control, ␤-actin was detected in all for the peptides.
13,14
The highly immunogenic nature of the foreign 65 kDa samples. Peritoneal cells and abdominal organs (spleen, liver and kidney) obtained from immunocompetent hsp molecule may similarly provide greatly enhanced, associated-recognition of tumour-associated antigen(s). Balb/c mice after hsp-liposome gene therapy did not express hsp65 mRNA (data not shown).
In preliminary experiments, J774 cells transduced with the mycobacterial hsp65 gene have been shown to be To assess the effect of hsp65 gene transfer on advanced tumours, experiments were carried out in Balb/c mice 2 more effective as antigen presenting cells than unmodified or vector-transduced control cells (B Stockinger, weeks after tumour implantation. Mice were injected with 2 × 10 6 cells into the peritoneum. Fourteen days later unpublished), suggesting that more efficient presentation 
Figure 4 Effect of in vivo hsp65 gene therapy on advanced tumours. Balb/c mice were injected with 2 × 10 6 J774 cells i.p. Fourteen days after tumour initiation 10 mice received i.p. injections of hsp65 DNA-liposome complexes repeated at 2 day intervals on four occasions (arrows). On day

Assessment of tumour size
Since tumours grew in most abdominal organs, resulting in an inseparable aggregation of primary tumours and abdominal organs, tumour size was calculated by weighing the primary tumour and abdominal organs of the test mice, and subtracting the average weight of abdominal organs obtained from five age-matched normal controls.
In vivo gene transfer
At various time-points after tumour induction, mice received four i.p. injections in 2 weeks, each containing 100 g plasmid DNA complexed with 400 g liposome (DOTAP; Boehringer Mannheim, Lewes, East Sussex, UK) at room temperature for 15 min before injection. Animals receiving the liposome-complexed plasmid DNA encoding the mycobacterial heat shock protein-65 
DNA histograms
Transfected and control cell lines, and cells obtained from the peritoneal cavity of mice were incubated with DNA specific dyes and assessed by flow cytometry 20 (FACScan; of tumour associated antigens could play a role in the Becton Dickinson UK, Oxford, UK). Peritoneal cell induction of antitumour immune response.
samples were first fixed with 1% paraformaldehyde in Studies by Srivastava and his colleagues 6,7,15 have dem-PBS, then incubated with 50 g/ml propidium iodide onstrated that mammalian hsps isolated from tumour (Sigma Chemical, Poole, UK) for 30 min on ice. DNA hiscells elicit protective immunity. Identical hsp fractions tograms were obtained for 10 000 cells in each sample. from normal tissues are not effective and tumour-derived hsps lose their protective effect after elution of small mRNA tumour-specific peptides 16 confirming that hsps function Total RNA was isolated from 2 × 10 6 peritoneal cell as chaperones for tumour-derived peptides. In our studsamples and approximately 2 × 3 mm sections of various ies, the presence of tumour-specific cytotoxic T cells elicorgans using guanidium thiocyanate-phenol-chloroform ited by hsp-transduced J774 cells in vivo (capable of lysing extraction and alcohol precipitation. both hsp-transduced and nonmodified tumour cells) 8, 9 After DNase treatment reverse transcription was carand production of J774-specific antibodies in mice receivried out as previously described. 21 PCR amplification was ing hsp65 gene transfer ( Figure 5 ) provide experimental performed using oligonucleotide mycobacterial hsp65-evidence for increased recognition of tumour antigens in specific primer pairs (5′-TTGAGCAGGTCCTCGTAC vivo. Hsp65 has been detected in the supernatant of hsp-TCA-3′ and 5′-ATGGCCAAGACAATTGCGTAC-3′) syntransfected cells, 17 it could also effectively transport (and thesised at the National Institute for Medical Research. protect from degradation) tumour-derived peptides to
The PCR mixture containing 1.25 l of each primer at 20 antigen presenting host cells eliciting immune response m was subjected to the following PCR conditions on an through both the MHC class I 18 and class II 19 dependent Omnigene (Hybaid, Middlesex, UK) TR3 SM2 thermopathways. Since the majority of human tumours express cycler: 35 cycles of 96°C/45 s; 60°C/45 s; 72°C/90 s, follow levels of MHC molecules, making direct presentation lowed by an extension cycle of 72°C for 5 min. The ␤-of their antigens to T cells ineffective, this mechanism actin primers were used as a control for both reverse may be crucial for the induction of an effective antitranscription and the PCR reaction itself. After amplifitumour immune response in humans.
cation, 10 l of reaction product and 2 l DNA loading buffer were electrophoresed in 1.5% agarose containing ethidium bromide (0.5 g/ml; Sigma Chemical) in 1 ×
Materials and methods
Tris-acetate EDTA buffer; molecular weight (mw) standards (kb ladder, BRL) were included. Bands were visuCells and cell cultures alised using a UV transilluminator and 65 kDa hsp-spe-J774G8 cells (J774) were maintained in DME with 10% cific bands were identified by anticipated mw. Hsp65 fetal calf serum, 100 g/ml streptomycin, 100 g/ml plasmid DNA (0.1 g/ml) was PCR amplified after penicillin, 1 mm l-glutamin and 10 mm Hepes.
reverse transcription and included as a positive control.
Detection of J774-specific antibodies Inoculation of mice with tumour cells Groups of 6 to 12-week-old female Balb/c and SCID mice Sera were collected from tumour bearing mice after in vivo gene transfer as described for genic structures to the plate. Wells were incubated with 343-348. 200 l of 1% BSA for 4 h to minimise nonspecific binding. 
